Results 11 to 20 of about 106,775 (245)

Glucagon-like peptide-1 receptor agonists in orthopaedics [PDF]

open access: yesSICOT-J
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F.   +7 more
doaj   +2 more sources

Signaling architecture of the glucagon-like peptide-1 receptor [PDF]

open access: yesJournal of Clinical Investigation
The glucagon-like peptide-1 receptor (GLP-1R) is a class B1 G protein-coupled receptor and major therapeutic target in type 2 diabetes and obesity. Beyond its canonical role in Gαs/cAMP signaling, GLP-1R is increasingly recognized as an organizer of spatiotemporally defined signaling nanodomains, or "signalosomes." This Review highlights our current ...
Gregory Austin, Alejandra Tomas
openaire   +3 more sources

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot [PDF]

open access: yesBiomedicines
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero   +3 more
doaj   +2 more sources

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]

open access: yesJournal of Arrhythmia
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal   +12 more
doaj   +2 more sources

Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR

open access: yesiScience, 2023
Summary: Crystal and cryo-EM structures of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) bound with their peptide ligands have been obtained with full-length constructs, indicating that the extracellular domain (ECD) is ...
Huixia Wang   +5 more
doaj   +1 more source

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

open access: yes, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu   +4 more
core   +5 more sources

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

open access: yes, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma [PDF]

open access: yesExploration of Asthma & Allergy
Glucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins.
Courtney Lehman, Ray Stokes Peebles Jr
doaj   +1 more source

Home - About - Disclaimer - Privacy